clinical trial · NCT06439563
Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
Peptic UlcerJP-1366 10 mgLanston Capsule 15 mgJP-1366 10 mg placeboLanston Capsule 15 mg placebo
brief summary
The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.
started
Oct 22, 2024
primary completion
Aug 1, 2027
completion
Dec 1, 2027
last updated
Nov 1, 2024
official title
A Multicenter, Parallel, Double-blind, Randomized, Active-controlled, Non-inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 Treatment in the Prevention of (NSAIDs)-Induced Peptic Ulcers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol